Cholangiocarcinoma Specialty Channel

Cholangiocarcinoma

Specialty Channel

Conference Coverage

Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma

05/28/2024

Allison Casey

According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...

According to a phase 2 trial...

05/28/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...

Results from the ORANGE II PLUS...

05/17/2024

Oncology

Conference Coverage

Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma

01/20/2024

Stephanie Holland

Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...

Results from a phase 2 study...

01/20/2024

Oncology

Conference Coverage

Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma

01/19/2024

Allison Casey

According to results from a phase 2 trial, combining hepatic arterial infusion pump chemotherapy with systemic therapy was associated with improved 3-year overall survival among patients with advanced intrahepatic cholangiocarcinoma.

According to results from a...

01/19/2024

Oncology

Conference Coverage

Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer

01/19/2024

Janelle Bradley

First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...

First-line treatment with...

01/19/2024

Oncology

News

Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer

11/02/2023

Allison Casey

On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.

On November 1, 2023, the FDA...

11/02/2023

Oncology

News

Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer

07/20/2023

Allison Casey

In a phase 2b study, zanidatamab demonstrated meaningful clinical benefit with a manageable safety profile among patients with HER2-positive, unresectable, locally advanced or metastatic biliary tract cancer.

In a phase 2b study, zanidatamab...

07/20/2023

Oncology

Conference Coverage

NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers

06/29/2023

Allison Casey

According to phase 3 data presented at the 2023 ESMO World Congress on Gastrointestinal Cancers, NUC-1031 plus cisplatin did not improve the overall survival among patients with advanced biliary tract cancers, vs gemcitabine-cisplatin.

According to phase 3 data...

06/29/2023

Oncology

Quiz

Adjuvant or Neoadjuvant Chemotherapy for Non-Metastatic Cholangiocarcinoma

06/15/2023

True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.

True or False: Patients with...

06/15/2023

Oncology

Quiz

Cholangioscopy for Diagnosis of Cholangiocarcinoma

06/15/2023

When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.

When used to diagnose...

06/15/2023

Oncology

Conference Coverage

Novel FGFR TKI Demonstrated Efficacy and Safety for Patients With Advanced Intrahepatic Cholangiocarcinoma

06/02/2023

Allison Casey

The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.

The FGFR-selective tyrosine...

06/02/2023

Oncology

News

Conference Coverage

Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma

05/28/2024

Allison Casey

According to a phase 2 trial...

05/28/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS...

05/17/2024

Oncology

Conference Coverage

Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma

01/20/2024

Stephanie Holland

Results from a phase 2 study...

01/20/2024

Oncology

Conference Coverage

Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma

01/19/2024

Allison Casey

According to results from a...

01/19/2024

Oncology

Conference Coverage

Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer

01/19/2024

Janelle Bradley

First-line treatment with...

01/19/2024

Oncology

News

Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer

11/02/2023

Allison Casey

On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.

On November 1, 2023, the FDA...

11/02/2023

Oncology

News

Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer

07/20/2023

Allison Casey

In a phase 2b study, zanidatamab...

07/20/2023

Oncology

Conference Coverage

NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers

06/29/2023

Allison Casey

According to phase 3 data...

06/29/2023

Oncology

Conference Coverage

Novel FGFR TKI Demonstrated Efficacy and Safety for Patients With Advanced Intrahepatic Cholangiocarcinoma

06/02/2023

Allison Casey

The FGFR-selective tyrosine kinase inhibitor (TKI) HMPL-453 was found to be effective and safe for patients with advanced intrahepatic cholangiocarcinoma.

The FGFR-selective tyrosine...

06/02/2023

Oncology

Conference Coverage

Nanvuranlat Demonstrated Clinical Activity for Advanced, Refractory Biliary Tract Cancers

01/20/2023

Allison Casey

According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the LAT1-inhibitor nanvuranlat significantly improved progression-free survival for patients with advanced refractory biliary tract cancers, compared...

According to a phase 2 trial...

01/20/2023

Oncology

Quiz

Adjuvant or Neoadjuvant Chemotherapy for Non-Metastatic Cholangiocarcinoma

06/15/2023

True or False: Patients with non-metastatic cholangiocarcinoma who received adjuvant or neoadjuvant chemotherapy had better median overall survival compared to patients who had surgery only.

True or False: Patients with...

06/15/2023

Oncology

Quiz

Cholangioscopy for Diagnosis of Cholangiocarcinoma

06/15/2023

When used to diagnose cholangiocarcinoma, or bile duct cancer, cholangioscopy yields a sensitivity of about ___.

When used to diagnose...

06/15/2023

Oncology

Quiz

Incidence of IDH Mutations in Cholangiocarcinoma

05/09/2023

In what percentage of patients with cholangiocarcinoma does an IDH mutation occur?

In what percentage of patients...

05/09/2023

Oncology

Quiz

Quiz: IDH Mutations in Biliary Tract Cancers

04/11/2023

Which type of biliary tract cancer is more likely to be IDH-mutant?

Which type of biliary tract...

04/11/2023

Oncology

Quiz

Quiz: Outcomes of Liver Transplant vs Resection for Perihilar Cholangiocarcinoma

12/01/2022

How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...

How did the outcomes of patients...

12/01/2022

Oncology

Quiz

Quiz: Trastuzumab Biosimilar Plus FOLFOX for HER2-Positive Biliary Tract Cancer

11/30/2022

What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?

What was the approximate...

11/30/2022

Oncology

Quiz

Quiz: In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with intrahepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?

11/02/2022

In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?

In the phase 2 FIDES-01 study,...

11/02/2022

Oncology

Test Your Knowledge

Quiz: What Test Can Be Used to Compare OS, DFS in ICC?

02/24/2022

Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?

Which test can be used to...

02/24/2022

Oncology

Quiz

Quiz: Which Clinical Trial Was the Basis for Pemagatinib Approval?

02/14/2022

The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.

The FDA’s approval of...

02/14/2022

Oncology

Test Your Knowledge

Quiz: Does Infigratinib Yield a Survival Benefit in Patients with Cholangiocarcinoma and FGFR2 Fusions?

08/28/2020

True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.

True or false: Infigratinib did...

08/28/2020

Oncology

Recent News

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Stephanie Holland

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

Pembrolizumab Plus Chemotherapy Approved for Treatment of Patients With Biliary Tract Cancer

11/02/2023

Allison Casey

On November 1, 2023, the FDA granted approval to pembrolizumab, with gemcitabine and cisplatin, for the treatment of locally advanced unresectable or metastatic biliary tract cancer.

On November 1, 2023, the FDA...

11/02/2023

Oncology

News

Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer

07/20/2023

Allison Casey

In a phase 2b study, zanidatamab...

07/20/2023

Oncology

News

Annual MRI for Patients With Primary Sclerosing Cholangitis Failed to Provide Long-Term Cholangiocarcinoma Survival Benefit

11/21/2022

Allison Casey

Among patients with primary sclerosing cholangitis, yearly surveillance by MRI was not able to detect cholangiocarcinoma early enough to convey a long-term survival benefit.

Among patients with primary...

11/21/2022

Oncology

News

Trastuzumab Biosimilar Plus FOLFOX Shows Promise for HER2-Positive Biliary Tract Cancers

11/10/2022

In a phase 2 trial, trastuzumab biosimilar plus FOLFOX demonstrated promising activity and acceptable safety among patients with HER2-positive biliary tract cancers that had progressed on gemcitabine and cisplatin chemotherapy regimens.

In a phase 2 trial, trastuzumab...

11/10/2022

Oncology

News

Novel FGFR2 Inhibitor Shows Promise in Patients With Cholangiocarcinoma and an FGFR2-Fusion or Rearrangement

10/20/2022

Allison Casey

According to a phase 1/2 study, the novel FGFR2-inhibitor RLY-4008 showed promised in patients with cholangiocarcinoma and an FGFR2 fusion or rearrangement.

According to a phase 1/2 study,...

10/20/2022

Oncology

News

FDA Approves Futibatinib for Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusions or Rearrangements

10/03/2022

Allison Casey

On September 30, 2022, the US FDA granted accelerated approval to futibatinib, 20 mg orally daily, for patients with locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements.

On September 30, 2022, the US...

10/03/2022

Oncology

News

Derazantinib Showed Clinical Benefit as a Second-Line Treatment for Patients With Intrahepatic Cholangiocarcinoma and EGFR2 Aberrations

09/30/2022

Allison Casey

Results from a phase 2 trial showed that derazantinib as a second-line treatment resulted in meaningful clinical benefit for patients with intrahepatic cholangiocarcinoma and EGFR2 aberrations.

Results from a phase 2 trial...

09/30/2022

Oncology

News

Nivolumab Plus Gemcitabine and S-1 Demonstrates Potential in Advanced Biliary Tract Cancer

09/28/2022

Allison Casey

Results from a phase 2 trial show that modified gemcitabine and S-1 plus nivolumab is a safe and promising regimen for patients with advanced biliary tract cancer, with impaired function of chromatin remodeling genes as a potential surrogate...

Results from a phase 2 trial...

09/28/2022

Oncology

News

Nivolumab Added to Chemotherapy or Ipilimumab Offers No Survival Benefit in Advanced Biliary Tract Cancer

08/31/2022

Allison Casey

Findings from a phase 2 trial suggest adding nivolumab to either chemotherapy or ipilimumab provides no PFS benefit in the first-line treatment of patients with advanced biliary tract cancer.

Findings from a phase 2 trial...

08/31/2022

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology